Azelastine + Fluticasone

Benefits at a glance

  • Combination of the two most widely used treatments for allergic rhinitis in one drug
  • Identical pump system as the proprietary drug
  • License rights available for all key territories

Product details

Indication:

Rhinitis (seasonal and perennial nasal allergy)

Strengths

137 µg + 50 µg

Dosage form

Nasal spray

API

Azelastine HCl
Fluticasone proprionate

Dossier available

Q3/2022

Turnover

92 Mio. € (IQVIA 2021 – EU)

Status

  • Development Kick-off
  • Formulation Development
  • Prototype
  • Pilot BE
  • Scale Up
  • 6 M Stability
  • Pivotal BE
  • Dossier
  • EU-Approval

Summary

The combination of the two most prevalent anti-rhinitis drugs, Azelastine and Fluticasone, has a strong evidence basis and is widely used for the treatment of seasonal nasal allergies. As a nasal spray, the product can be used on the go and without swallowing or water, therefore offering a noninvasive alternative. Azelastine + Fluticasone is also approved for long term use, offering patients with a consistent and safe treatment.

Approximately 20% of people suffering from seasonal nasal allergies. Azelastine and Fluticasone nasal spray not only offer an established and patient-friendly treatment option but can unlock a large market potential.

 

Your Contact

Heike Sagi

Heike Sagi

Business Development & Licensing
Senior Director

Midas Pharma GmbH
Rheinstraße 49
55218 Ingelheim
Germany
  • Disclaimer

    The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.

     

Share this page